合成新型 1,2,3-三唑-腙混合物:靶向胆碱酯酶和阿尔茨海默氏症相关基因。

IF 3.2 4区 医学 Q3 CHEMISTRY, MEDICINAL
Future medicinal chemistry Pub Date : 2024-08-02 Epub Date: 2024-06-12 DOI:10.1080/17568919.2024.2359894
Diba Shareghi-Boroujeni, Aida Iraji, Mahintaj Dara, Mohammad Hashem Hashempur, Shahrokh Zare, Roshanak Hariri, Tahmineh Akbarzadeh, Mina Saeedi
{"title":"合成新型 1,2,3-三唑-腙混合物:靶向胆碱酯酶和阿尔茨海默氏症相关基因。","authors":"Diba Shareghi-Boroujeni, Aida Iraji, Mahintaj Dara, Mohammad Hashem Hashempur, Shahrokh Zare, Roshanak Hariri, Tahmineh Akbarzadeh, Mina Saeedi","doi":"10.1080/17568919.2024.2359894","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> A new series of 1,2,3-triazole-hydrazone derivatives were developed to evaluate their anti-Alzheimer's activity. <b>Materials & methods:</b> All compounds were screened toward cholinesterases via the modified Ellman's method. The toxicity assay on SH-SY5Y cells was performed using the MTT assay, and the expression levels of <i>GSK-3α</i>, <i>GSK-3β</i>, <i>DYRK1</i> and <i>CDK5</i> were assessed in the presence of compounds <b>6m</b> and <b>6p</b>.<b>Results:6m</b> and <b>6p</b>; acting as mixed-type inhibitors, exhibited promising acetylcholinesterase and butyrylcholinesterase inhibitory activity, respectively. <b>6m</b> demonstrated no toxicity under tested concentrations on the SH-SY5Y cells and positively impacted neurodegenerative pathways. Notably, <b>6m</b> displayed a significant downregulation in mRNA levels of <i>GSK-3α</i>, <i>GSK-3β</i> and <i>CDK5</i>.<b>Conclusion:</b> The target compounds could be considered in developing anti-Alzheimer's disease agents.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1519-1535"},"PeriodicalIF":3.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370907/pdf/","citationCount":"0","resultStr":"{\"title\":\"Synthesis of novel hybrids of 1,2,3-triazoles-hydrazone: targeting cholinesterases and Alzheimer's related genes.\",\"authors\":\"Diba Shareghi-Boroujeni, Aida Iraji, Mahintaj Dara, Mohammad Hashem Hashempur, Shahrokh Zare, Roshanak Hariri, Tahmineh Akbarzadeh, Mina Saeedi\",\"doi\":\"10.1080/17568919.2024.2359894\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> A new series of 1,2,3-triazole-hydrazone derivatives were developed to evaluate their anti-Alzheimer's activity. <b>Materials & methods:</b> All compounds were screened toward cholinesterases via the modified Ellman's method. The toxicity assay on SH-SY5Y cells was performed using the MTT assay, and the expression levels of <i>GSK-3α</i>, <i>GSK-3β</i>, <i>DYRK1</i> and <i>CDK5</i> were assessed in the presence of compounds <b>6m</b> and <b>6p</b>.<b>Results:6m</b> and <b>6p</b>; acting as mixed-type inhibitors, exhibited promising acetylcholinesterase and butyrylcholinesterase inhibitory activity, respectively. <b>6m</b> demonstrated no toxicity under tested concentrations on the SH-SY5Y cells and positively impacted neurodegenerative pathways. Notably, <b>6m</b> displayed a significant downregulation in mRNA levels of <i>GSK-3α</i>, <i>GSK-3β</i> and <i>CDK5</i>.<b>Conclusion:</b> The target compounds could be considered in developing anti-Alzheimer's disease agents.</p>\",\"PeriodicalId\":12475,\"journal\":{\"name\":\"Future medicinal chemistry\",\"volume\":\" \",\"pages\":\"1519-1535\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370907/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17568919.2024.2359894\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2359894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:开发了一系列新的 1,2,3-三唑-腙衍生物,以评估它们的抗阿尔茨海默氏症活性。材料与方法:通过改良的埃尔曼法对所有化合物进行胆碱酯酶筛选。采用 MTT 法对 SH-SY5Y 细胞进行毒性检测,并在化合物 6m 和 6p 存在的情况下评估 GSK-3α、GSK-3β、DYRK1 和 CDK5 的表达水平。结果显示作为混合型抑制剂,6m 和 6p 分别表现出良好的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。在测试浓度下,6m 对 SH-SY5Y 细胞无毒性,并对神经退行性途径产生积极影响。值得注意的是,6m 能显著下调 GSK-3α、GSK-3β 和 CDK5 的 mRNA 水平。结论目标化合物可用于开发抗阿尔茨海默病药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Synthesis of novel hybrids of 1,2,3-triazoles-hydrazone: targeting cholinesterases and Alzheimer's related genes.

Aim: A new series of 1,2,3-triazole-hydrazone derivatives were developed to evaluate their anti-Alzheimer's activity. Materials & methods: All compounds were screened toward cholinesterases via the modified Ellman's method. The toxicity assay on SH-SY5Y cells was performed using the MTT assay, and the expression levels of GSK-3α, GSK-3β, DYRK1 and CDK5 were assessed in the presence of compounds 6m and 6p.Results:6m and 6p; acting as mixed-type inhibitors, exhibited promising acetylcholinesterase and butyrylcholinesterase inhibitory activity, respectively. 6m demonstrated no toxicity under tested concentrations on the SH-SY5Y cells and positively impacted neurodegenerative pathways. Notably, 6m displayed a significant downregulation in mRNA levels of GSK-3α, GSK-3β and CDK5.Conclusion: The target compounds could be considered in developing anti-Alzheimer's disease agents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信